BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Seagen Survival Data Offer New Hope for Hodgkin Lymphoma Patients

  Data from Phase III ECHELON-1 clinical study conducted with either stage III or stage IV cHL showed consistent improvement in OS across each of the six 28-day cycles completed.

  February 4, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Precision Nutrition – the Untapped Reservoir in Cancer Therapeutics

  Preclinical models indicate that pairing specific cancer treatments with precision nutritional interventions increased treatment efficacy by as much as 500%.

  February 4, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Policy

  Biogen’s Aduhelm Grabs the Spotlight at User Fee Renewals Hearing

  This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.

  February 4, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Financials Indicate Novartis’ Sandoz Division Could Be a Tough Sell

  Novartis reported its full-year financials this week for 2021, and overall, the news was good. Of concern, however, is the company’s Sandoz generics unit.

  February 4, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  New Leaders Take the Helm at Three Biopharma Companies

  StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.

  February 4, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Pharm Country

  Sanofi Unites as One Under New Logo, Structure

  After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of its corporate umbrella supporting its three-year-old “Play to Win” strategy.

  February 4, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  BioCapital

  Cell Therapy Player Arcellx Now Trading on the Nasdaq

  Gaithersburg, Maryland-based Arcellx, Inc. unveiled its ticker symbol on the Nasdaq Friday, hitting the market at a cool $15 per share.

  February 4, 2022

   · 

  2 min read

   · 

  Claudia Beezhold
• 

  Drug Development

  Two Pharma Companies Begin February with Hits and Misses

  UCB hit the mark in its Phase III clinical trial assessing zilucoplan, while Vanda failed its late-stage study of tradipitant.

  February 4, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Gamida, Unity Layoffs Illustrate Challenges Faced by Small Biotech

  On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.

  February 4, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Pfizer-Partnered Lyme Disease Vaccine on Track for Phase III

  Specialty vaccine company Valneva and Pfizer have reported positive Phase II data from their clinical trial evaluating a Lyme Disease vaccine candidate.

  February 4, 2022

   · 

  2 min read

   · 

  Hayley Shasteen